Cargando…

Clinical Characteristics of Immune Response in Asymptomatic Carriers and Symptomatic Patients With COVID-19

The pandemic of coronavirus disease 2019 (COVID-19) has emerged as a major public health challenge worldwide. A comprehensive understanding of clinical characteristics and immune responses in asymptomatic carriers and symptomatic patients with COVID-19 is of great significance to the countermeasures...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Entao, Wang, Shen, He, Wenwen, He, Jun, Liu, Luogeng, Zhang, Xiaotuan, Yang, Songtao, Yan, Feihu, Gao, Yuwei, Liu, Bin, Xia, Xianzhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171238/
https://www.ncbi.nlm.nih.gov/pubmed/35685940
http://dx.doi.org/10.3389/fmicb.2022.896965
_version_ 1784721622529212416
author Li, Entao
Wang, Shen
He, Wenwen
He, Jun
Liu, Luogeng
Zhang, Xiaotuan
Yang, Songtao
Yan, Feihu
Gao, Yuwei
Liu, Bin
Xia, Xianzhu
author_facet Li, Entao
Wang, Shen
He, Wenwen
He, Jun
Liu, Luogeng
Zhang, Xiaotuan
Yang, Songtao
Yan, Feihu
Gao, Yuwei
Liu, Bin
Xia, Xianzhu
author_sort Li, Entao
collection PubMed
description The pandemic of coronavirus disease 2019 (COVID-19) has emerged as a major public health challenge worldwide. A comprehensive understanding of clinical characteristics and immune responses in asymptomatic carriers and symptomatic patients with COVID-19 is of great significance to the countermeasures of patients with COVID-19. Herein, we described the clinical information and laboratory findings of 43 individuals from Hunan Province, China, including 13 asymptomatic carriers and 10 symptomatic patients with COVID-19, as well as 20 healthy controls in the period from 25 January to 18 May 2020. The serum samples of these individuals were analyzed to measure the cytokine responses, receptor-binding domain (RBD), and nucleocapsid (N) protein-specific antibody titers, as well as SARS-CoV-2 neutralizing antibodies (nAbs). For cytokines, significantly higher Th1 cytokines including IL-2, IL-8, IL-12p70, IFN-γ, and TNF-α, as well as Th2 cytokines including IL-10 and IL-13 were observed in symptomatic patients compared with asymptomatic carriers. Compared with symptomatic patients, higher N-specific IgG4/IgG1 ratio and RBD-specific/N-specific IgG1 ratio were observed in asymptomatic carriers. Comparable nAbs were detected in both asymptomatic carriers and symptomatic patients with COVID-19. In the symptomatic group, nAbs in patients with underlying diseases were weaker than those of patients without underlying diseases. Our retrospective study will enrich and verify the clinical characteristics and serology diversities in asymptomatic carriers and symptomatic patients with COVID-19.
format Online
Article
Text
id pubmed-9171238
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91712382022-06-08 Clinical Characteristics of Immune Response in Asymptomatic Carriers and Symptomatic Patients With COVID-19 Li, Entao Wang, Shen He, Wenwen He, Jun Liu, Luogeng Zhang, Xiaotuan Yang, Songtao Yan, Feihu Gao, Yuwei Liu, Bin Xia, Xianzhu Front Microbiol Microbiology The pandemic of coronavirus disease 2019 (COVID-19) has emerged as a major public health challenge worldwide. A comprehensive understanding of clinical characteristics and immune responses in asymptomatic carriers and symptomatic patients with COVID-19 is of great significance to the countermeasures of patients with COVID-19. Herein, we described the clinical information and laboratory findings of 43 individuals from Hunan Province, China, including 13 asymptomatic carriers and 10 symptomatic patients with COVID-19, as well as 20 healthy controls in the period from 25 January to 18 May 2020. The serum samples of these individuals were analyzed to measure the cytokine responses, receptor-binding domain (RBD), and nucleocapsid (N) protein-specific antibody titers, as well as SARS-CoV-2 neutralizing antibodies (nAbs). For cytokines, significantly higher Th1 cytokines including IL-2, IL-8, IL-12p70, IFN-γ, and TNF-α, as well as Th2 cytokines including IL-10 and IL-13 were observed in symptomatic patients compared with asymptomatic carriers. Compared with symptomatic patients, higher N-specific IgG4/IgG1 ratio and RBD-specific/N-specific IgG1 ratio were observed in asymptomatic carriers. Comparable nAbs were detected in both asymptomatic carriers and symptomatic patients with COVID-19. In the symptomatic group, nAbs in patients with underlying diseases were weaker than those of patients without underlying diseases. Our retrospective study will enrich and verify the clinical characteristics and serology diversities in asymptomatic carriers and symptomatic patients with COVID-19. Frontiers Media S.A. 2022-05-24 /pmc/articles/PMC9171238/ /pubmed/35685940 http://dx.doi.org/10.3389/fmicb.2022.896965 Text en Copyright © 2022 Li, Wang, He, He, Liu, Zhang, Yang, Yan, Gao, Liu and Xia. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Li, Entao
Wang, Shen
He, Wenwen
He, Jun
Liu, Luogeng
Zhang, Xiaotuan
Yang, Songtao
Yan, Feihu
Gao, Yuwei
Liu, Bin
Xia, Xianzhu
Clinical Characteristics of Immune Response in Asymptomatic Carriers and Symptomatic Patients With COVID-19
title Clinical Characteristics of Immune Response in Asymptomatic Carriers and Symptomatic Patients With COVID-19
title_full Clinical Characteristics of Immune Response in Asymptomatic Carriers and Symptomatic Patients With COVID-19
title_fullStr Clinical Characteristics of Immune Response in Asymptomatic Carriers and Symptomatic Patients With COVID-19
title_full_unstemmed Clinical Characteristics of Immune Response in Asymptomatic Carriers and Symptomatic Patients With COVID-19
title_short Clinical Characteristics of Immune Response in Asymptomatic Carriers and Symptomatic Patients With COVID-19
title_sort clinical characteristics of immune response in asymptomatic carriers and symptomatic patients with covid-19
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171238/
https://www.ncbi.nlm.nih.gov/pubmed/35685940
http://dx.doi.org/10.3389/fmicb.2022.896965
work_keys_str_mv AT lientao clinicalcharacteristicsofimmuneresponseinasymptomaticcarriersandsymptomaticpatientswithcovid19
AT wangshen clinicalcharacteristicsofimmuneresponseinasymptomaticcarriersandsymptomaticpatientswithcovid19
AT hewenwen clinicalcharacteristicsofimmuneresponseinasymptomaticcarriersandsymptomaticpatientswithcovid19
AT hejun clinicalcharacteristicsofimmuneresponseinasymptomaticcarriersandsymptomaticpatientswithcovid19
AT liuluogeng clinicalcharacteristicsofimmuneresponseinasymptomaticcarriersandsymptomaticpatientswithcovid19
AT zhangxiaotuan clinicalcharacteristicsofimmuneresponseinasymptomaticcarriersandsymptomaticpatientswithcovid19
AT yangsongtao clinicalcharacteristicsofimmuneresponseinasymptomaticcarriersandsymptomaticpatientswithcovid19
AT yanfeihu clinicalcharacteristicsofimmuneresponseinasymptomaticcarriersandsymptomaticpatientswithcovid19
AT gaoyuwei clinicalcharacteristicsofimmuneresponseinasymptomaticcarriersandsymptomaticpatientswithcovid19
AT liubin clinicalcharacteristicsofimmuneresponseinasymptomaticcarriersandsymptomaticpatientswithcovid19
AT xiaxianzhu clinicalcharacteristicsofimmuneresponseinasymptomaticcarriersandsymptomaticpatientswithcovid19